Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

Objective. To perform a systematic evaluation of the efficacy and safety of combined treatment of Shenmai injection and chemotherapy for lung cancer. Methods. A literature search for randomized controlled trials (RCTs) describing the treatment of lung cancer by Shenmai injection and chemotherapy or chemotherapy alone was performed using the PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Value In Paper (VIP), China BioMed, and Wanfang databases. The databases were searched for entries published before September 1, 2019. Results. Thirty-seven RCTs, comprising a total of 2808 cases, were included in the present meta-analysis. Of these, 1428 cases were treated by Shenmai injection plus chemotherapy, and 1380 cases were treated only by chemotherapy. The results of meta-analysis showed that the combined treatment (Shenmai injection plus chemotherapy) increased the short-term efficacy of treatment (relative risk [RR] = 1.183, 95% confidence interval [CI] = 1.043–1.343, P < 0.01 ) and improved patients’ quality of life (RR = 1.514, 95%CI = 1.211–1.891, P < 0.01 ) compared with chemotherapy alone. With regard to the adverse effects, the combined treatment markedly reduced the incidence of white blood cell (WBC) reduction (RR = 0.846, 95%CI = 0.760–0.941, P < 0.01 ), platelet reduction (RR = 0.462, 95% CI = 0.330–0.649, P < 0.01 ), and hemoglobin reduction (RR = 0.462, 95% CI = 0.330–0.649, P < 0.01 ) and alleviated drug-induced liver injury (RR = 0.677, 95%CI = 0.463–0.990, P < 0.05 ). However, it did not offer a significant protective effect (RR = 0.725, 95%CI = 0.358–1.468, P < 0.05 ). The effect of the combined treatment on the occurrence of vomiting was considerable (RR = 0.889, 95%CI = 0.794–0.996, P < 0.05 ), and the combined treatment markedly increased the immunity of patients with lung cancer. Conclusion. The combined treatment of Shenmai injection plus chemotherapy enhanced the short-term efficacy of chemotherapy, improved the patient quality of life, alleviated the adverse effects of chemotherapeutics, and increased the patient immunity. These results should be confirmed by large-scale, high-quality RCTs.

Download Full-text

CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study

World Journal of Surgical Oncology ◽

10.1186/s12957-018-1368-8 ◽

2018 ◽

Vol 16 (1) ◽

Cited By ~ 17

Author(s):

Baolin Wu ◽

Jun Zhou ◽

Gonghao Ling ◽

Dongyong Zhu ◽

Qingyun Long

Keyword(s):

Hepatocellular Carcinoma ◽

Transarterial Chemoembolization ◽

Efficacy And Safety ◽

Short Term ◽

Safety Study ◽

Term Efficacy ◽

Drug Eluting Beads ◽

Drug Eluting

Download Full-text

Short-term Efficacy and Safety of Tolvaptan for the Refractory Heart Failure of the Elderly Patients

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2012.08.303 ◽

2012 ◽

Vol 18 (10) ◽

pp. S181

Author(s):

Hajime Fujimoto ◽

Kazumasa Harada

Keyword(s):

Heart Failure ◽

Elderly Patients ◽

The Elderly ◽

Efficacy And Safety ◽

Short Term ◽

Term Efficacy ◽

Refractory Heart Failure

Download Full-text

Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

The Journal of Headache and Pain ◽

10.1186/s10194-020-01138-x ◽

2020 ◽

Vol 21 (1) ◽

Cited By ~ 1

Author(s):

Min Hou ◽

Haiyan Xing ◽

Chen Li ◽

Xianfeng Wang ◽

Dongmei Deng ◽

...

Keyword(s):

Systematic Review ◽

Acute Treatment ◽

Receptor Agonist ◽

Meta Analysis ◽

Efficacy And Safety ◽

Short Term ◽

Term Efficacy

Download Full-text

Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices

The Journal of Heart and Lung Transplantation ◽

10.1016/j.healun.2019.01.951 ◽

2019 ◽

Vol 38 (4) ◽

pp. S374

Author(s):

T. Fujino ◽

T. Imamura ◽

D. Nitta ◽

G. Kim ◽

A.J. Kanelidis ◽

...

Keyword(s):

Left Ventricular ◽

Ventricular Assist Devices ◽

Efficacy And Safety ◽

Left Ventricular Assist Devices ◽

Short Term ◽

Ventricular Assist ◽

Assist Devices ◽

Term Efficacy ◽

Left Ventricular Assist

Download Full-text

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

Clinical Ophthalmology ◽

10.2147/opth.s31085 ◽

2012 ◽

pp. 771 ◽

Cited By ~ 5

Author(s):

Kenji Inoue ◽

Mieko Masumoto ◽

Risako Higa ◽

Masato Wakakura ◽

Hiromi Kohmoto ◽

...

Keyword(s):

Fixed Combination ◽

Efficacy And Safety ◽

Timolol Maleate

Download Full-text

Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies

BMC Cancer ◽

10.1186/s12885-020-07527-4 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Bo Wang ◽

Lu Xu ◽

Qihuan Li ◽

Sailimai Man ◽

Cheng Jin ◽

...

Keyword(s):

Cohort Studies ◽

Advanced Nsclc ◽

Meta Analysis ◽

Efficacy And Safety ◽

Cardiovascular Toxicity ◽

Short Term ◽

Quality Of Evidence ◽

Term Efficacy ◽

Safety Outcomes

Abstract Background Both intermittent intravenous (IIV) infusion and continuous intravenous (CIV) infusion of Endostar are widely used for NSCLC in China. We aimed to compare the efficacy and safety of CIV of Endostar versus IIV in combination with first-line chemotherapy for patients with advanced NSCLC. Methods RCTs, NRCTs and cohort studies which compared CIV of Endostar with IIV in advanced NSCLC patients and reported efficacy or safety outcomes were eligible. Two reviewers independently screened records, extracted data and assessed risk of bias. Pooled risk ratios (RRs) with 95% confidence intervals were calculated using random effects meta-analysis for short-term efficacy and safety outcomes, and hazard ratios (HRs) for survival outcomes. Results Finally nine studies involving 597 patients were included, containing two RCTs, three NRCTs and four cohort studies. For short-term efficacy, moderate quality of evidence showed that there were no significant differences between CIV of Endostar and IIV in objective response rate (ORR; RR 1.34, 95% CI 0.91–1.98, P = 0.14) and disease control rate (DCR; RR 1.11, 95% CI 0.94–1.30, P = 0.21). Very low quality of evidence indicated that CIV of Endostar significantly improved both overall survival (OS; HR 0.69, 95% CI 0.48–0.99, P = 0.046) and progression-free survival (PFS; HR 0.71, 95% CI 0.55–0.93, P = 0.01) compared with IIV. As for safety outcomes, moderate quality of evidence found that CIV of Endostar significantly reduced the risk of myelosuppression (RR 0.55, 95% CI 0.32–0.96, P = 0.03) and cardiovascular toxicity (RR 0.21, 95% CI 0.06–0.78, P = 0.02) compared with IIV. Conclusions In advanced NSCLC, compared with IIV, CIV of Endostar had similar short-term efficacy, and substantially lower risk of myelosuppression and cardiovascular toxicity. Although very low quality of evidence supported the survival benefit of CIV compared with IIV, large RCTs with long-term follow-up are needed to demonstrate survival benefits. Caution should be given for off-label use of CIV of Endostar.

Download Full-text